@article{ac13791010ee4f6f96c7cef9cd48ca42,
title = "Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma",
abstract = "Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.",
keywords = "adverse events, hepatocellular carcinoma, sorafenib, tolerable adverse events protocol, toxicity, tumor response, adverse events, hepatocellular carcinoma, sorafenib, tolerable adverse events protocol, toxicity, tumor response",
author = "Antonio Gasbarrini and Ponziani, {Francesca Romana} and Sherrie Bhoori and Alessandro Germini and Marco Bongini and Maria Flores and Carlo Sposito and Antonio Facciorusso and Vincenzo Mazzaferro",
year = "2015",
doi = "10.1111/liv.13052",
language = "English",
pages = "N/A--N/A",
journal = "Liver International",
issn = "1478-3223",
publisher = "-MALDEN, USA: WILEY-BLACKWELL PUBLISHING -Copenhagen K Denmark: Blackwell Munksgaard",
}